| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/12/2006 | CN1759123A Uses of IL-23 agonists and antagonists; related reagents |
| 04/12/2006 | CN1759122A Methods and compositions involving MDA-7 |
| 04/12/2006 | CN1758924A Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
| 04/12/2006 | CN1758922A Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 04/12/2006 | CN1758921A Storage-stable and bio-stable formulations of ACE inhibitors, and methods for preparation thereof |
| 04/12/2006 | CN1758916A Method of treating and preventing hyperparathyroidism with vitamin D2 or D4 compounds |
| 04/12/2006 | CN1758900A Pharmaceutical composition |
| 04/12/2006 | CN1757736A Construction expression of fusion gene carrier and its application |
| 04/12/2006 | CN1757727A Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action |
| 04/12/2006 | CN1757413A Antibody inhibition body fluid immunity of using special integrated CD40CR(CD40 part) |
| 04/12/2006 | CN1757398A Method for preparing inorganic salt nanometer particles containing and packing traditional Chinese medicine and its application |
| 04/12/2006 | CN1250732C 病毒株 Strains |
| 04/12/2006 | CN1250731C Packaging of positive-strand RNA virus replicon particles |
| 04/12/2006 | CN1250721C Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
| 04/12/2006 | CN1250718C Chromatography purification process of viper venom blood clotting enzyme |
| 04/12/2006 | CN1250717C Human Enzymes of metalloprotease family |
| 04/12/2006 | CN1250711C Purging of cells using viruses |
| 04/12/2006 | CN1250571C Specific binding molecules for scintigraphy, conjugates containing them and uses |
| 04/12/2006 | CN1250570C Binding molecules derived from immunolobulins which do not trigger complement mediated lysis |
| 04/12/2006 | CN1250566C Chemically modified polypeptides |
| 04/12/2006 | CN1250286C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 04/12/2006 | CN1250285C Cellular vesicle called 'exosome', prepn. and use thereof in immune stimulation |
| 04/12/2006 | CN1250284C Hepatitis A inactivated vaccine |
| 04/12/2006 | CN1250283C Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 04/12/2006 | CN1250282C Stable protein compositions |
| 04/12/2006 | CN1250281C Method for treating endothelium wound |
| 04/12/2006 | CN1250280C Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 04/12/2006 | CN1250279C Liposome targeting of matrix metalloproteinase inhibitors |
| 04/12/2006 | CN1250219C Pharmaceutical composition |
| 04/12/2006 | CN1250114C Health foods containing natto kinase and fermented milk products |
| 04/11/2006 | US7026524 Human coagulation factor VII variants |
| 04/11/2006 | US7026485 inhibitors of HIV protease; N-heterocyclic moiety containing hydroxyethylamine compounds where the heterocyclic moiety may be octahydroisoquinoline |
| 04/11/2006 | US7026466 Serotonin-gated anion channel |
| 04/11/2006 | US7026462 Regulation of angiogenesis with zinc finger proteins |
| 04/11/2006 | US7026461 Engineered protein kinases which can utilize nucleotide triphosphate substrates |
| 04/11/2006 | US7026457 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| 04/11/2006 | US7026452 Human mitochondrial proteins and polynucleotides encoding the proteins |
| 04/11/2006 | US7026451 Small and intermediate conductance, calcium-activated potassium channels and uses thereof |
| 04/11/2006 | US7026449 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/11/2006 | US7026447 53 human secreted proteins |
| 04/11/2006 | US7026445 Human SDF-5 protein and compositions |
| 04/11/2006 | US7026444 Comprises extracellular novel receptor advanced glycosylation endproducts (EN-RAGE) for treatment and prevention of inflammation and neurodegenerative diseases |
| 04/11/2006 | US7026443 Composition including an oligopeptide 13 residues or less in length, which comprises the sequence ATLERTEVY (SEQ ID NO:31040); use in epitope-based vaccines |
| 04/11/2006 | US7026431 Sustained release ionic conjugate |
| 04/11/2006 | US7026329 Administering to a patient suffering from the pain an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of nalmefene effective to enhance the analgesic potency |
| 04/11/2006 | US7026324 Amide containing a pyridinone or pyrazinone compound as serine protease enzyme inhibitors |
| 04/11/2006 | US7026300 One step immunization procedure for inducing a Chlamydia specific immune response |
| 04/11/2006 | US7026299 Stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. |
| 04/11/2006 | US7026297 Neuroprotective agents |
| 04/11/2006 | US7026296 Prevent cytokine biosynthesis; topical applying to eye |
| 04/11/2006 | US7026295 Administering a lactoferrin formulation to provide therapy for cardiovascular disease |
| 04/11/2006 | US7026294 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes |
| 04/11/2006 | US7026293 Comprising active ingredient such as atrial natriuretic peptide which can increase cGMP production by acting on natriuretic peptide receptor, and which reduces an infarct region |
| 04/11/2006 | US7026292 improving the tissue inductive activity of BMPs, especially in a jaw bone for use in periodontal or dental reconstructive procedures; inducing local tissue formation from a progenitor cell using prosthetic devices coated with the factor |
| 04/11/2006 | US7026291 Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| 04/11/2006 | US7026290 surfactant; an amphiphilic solvent comprising a lower alkyl hydroxy alkanoic acid ester or an N-alkyl pyrrolidone; and a cyclosporin; capable of forming particles of a size of less than about 100 nm upon contact with an aqueous solution |
| 04/11/2006 | US7026289 Method and compositions for treating hyperlipidemia and other conditions |
| 04/11/2006 | US7026288 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
| 04/11/2006 | US7026287 Treating pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. |
| 04/11/2006 | US7026286 Methods and compositions for the introduction of molecules into cells |
| 04/11/2006 | US7026285 Immunomodulating polymers |
| 04/11/2006 | US7026284 Formative agent of protein complex |
| 04/11/2006 | US7026283 Calcium-independent negative regulation by CD81 of receptor signalling |
| 04/11/2006 | US7026282 including units from amino acids with cyclopentyl, cyclohexyl, cycloheptyl or decahydronaphthalenyl rings; inhibitors of the binding interaction between human urokinase plasminogen activator and its cell surface receptor; treatment of cancer |
| 04/11/2006 | US7026281 Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| 04/11/2006 | US7026280 Polypeptides; nervous system, brain disorders |
| 04/11/2006 | US7026167 Systems and methods for the analysis of protein phosphorylation |
| 04/11/2006 | US7026157 Bacterial hemoglobin receptor genes |
| 04/11/2006 | US7026140 Serum paraoxonase |
| 04/11/2006 | US7026139 To regulate an immune response in an animal |
| 04/11/2006 | US7026130 screening chemical compounds for ability to compete with hepatitis C virus for binding to a HCV receptor by comparing the binding of the HCV receptor to the E2 protein of HCV in the presence of said compound to the binding of the receptor to the protein in the absence of the compound |
| 04/11/2006 | US7026128 Nucleotide sequences coding polypeptide for use as diagnostic tool in the detection of allergic response to mammalian animal dander |
| 04/11/2006 | US7026118 use of CaN subunit B for the manufacture of medicament for the treatment of mammalian cancer by regulating the immune system. |
| 04/11/2006 | US7026114 Methods and compositions for monitoring polymer array synthesis |
| 04/11/2006 | US7025987 Delivery system for nucleic acids |
| 04/11/2006 | US7025983 Water soluble film forming polymer |
| 04/11/2006 | US7025968 Identifying viricidal agents which prevent cytomegalo viral infection and distribution; gene expression inhibition |
| 04/11/2006 | US7025964 Peptide-based immunotherapeutic agent |
| 04/11/2006 | US7025962 Gene encoding lymphocyte surface antigen; protein or nucleic acid |
| 04/11/2006 | US7025960 For therapy of diseases which can be treated or alleviated by a stimulation of the production of cytokines, particularly of IL-12 |
| 04/11/2006 | US7025959 Drug containing Dna coding of protein; hybrids; genetic engineering |
| 04/11/2006 | US7025957 Topically applied to darkened skin areas |
| 04/11/2006 | US7025951 Topically applying to the skin a peptide containing a nitroguanidine group |
| 04/11/2006 | US7025515 Bit mask generation system |
| 04/11/2006 | CA2358829C Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 04/11/2006 | CA2321177C Recombinant fibronectin-based extracellular matrix for wound healing |
| 04/11/2006 | CA2204375C Methods for the diagnosis of glaucoma |
| 04/06/2006 | WO2006037029A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 04/06/2006 | WO2006036962A2 Compositions and methods for modulating tissue regeneration and chemotactic responses |
| 04/06/2006 | WO2006036919A2 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 04/06/2006 | WO2006036892A2 Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| 04/06/2006 | WO2006036860A2 Kallikrein inhibitors and uses thereof |
| 04/06/2006 | WO2006036804A2 Methods for the treatment and prevention of diseases of biological conduits |
| 04/06/2006 | WO2006036729A2 USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS |
| 04/06/2006 | WO2006036700A2 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 04/06/2006 | WO2006036613A2 Mracs as modifiers of the rac pathway and methods of use |
| 04/06/2006 | WO2006036465A2 Compositions and methods for treating cystic fibrosis |
| 04/06/2006 | WO2006036445A2 Chimeric nk receptor and methods for treating cancer |
| 04/06/2006 | WO2006036406A2 Live microbial microbicides |
| 04/06/2006 | WO2006036371A2 Combination therapy |